134 related articles for article (PubMed ID: 33770058)
1. FOXA1 Expression by Immunohistochemistry in Carcinosarcomas of the Endometrium and Ovary/Fallopian Tube.
Karpathiou G; Chauleur C; Dal Col P; Peoc'h M
Int J Gynecol Pathol; 2021 Nov; 40(6):611-616. PubMed ID: 33770058
[TBL] [Abstract][Full Text] [Related]
2. CD34 immunohistochemistry in female genital tract carcinosarcoma (malignant mixed müllerian tumors) supports a dominant role of the carcinomatous component.
Costa MJ; Guinee D
Appl Immunohistochem Mol Morphol; 2000 Dec; 8(4):293-9. PubMed ID: 11127921
[TBL] [Abstract][Full Text] [Related]
3. Mutational and Immunophenotypic Profiling of a Series of 8 Tubo-ovarian Carcinosarcomas Revealed a Monoclonal Origin of the Disease.
Trento M; Munari G; Carraro V; Lanza C; Salmaso R; Pizzi S; Santoro L; Chiarelli S; Dal Santo L; Nardelli GB; Saccardi C; Nicoletto O; Baldoni A; Rugge M; Fassan M
Int J Gynecol Pathol; 2020 Jul; 39(4):305-312. PubMed ID: 31688243
[TBL] [Abstract][Full Text] [Related]
4. Folate Receptor Alpha Is Preferentially Expressed in the Carcinoma Component of Endometrial Carcinosarcomas: A Potential Target for Adjuvant Therapy.
Hanley KZ; Horowitz IR; Gordon A; Meisel J; Khanna N
Int J Gynecol Pathol; 2021 Sep; 40(5):501-509. PubMed ID: 33323854
[TBL] [Abstract][Full Text] [Related]
5. Carcinoma (malignant mixed müllerian [mesodermal] tumor) of the uterus and ovary. Correlation of clinical, pathologic, and immunohistochemical features in 29 cases.
Costa MJ; Khan R; Judd R
Arch Pathol Lab Med; 1991 Jun; 115(6):583-90. PubMed ID: 1710102
[TBL] [Abstract][Full Text] [Related]
6. Uterine carcinosarcoma and high-risk endometrial carcinomas: a clinicopathological comparison.
Zhang C; Hu W; Jia N; Li Q; Hua K; Tao X; Wang L; Feng W
Int J Gynecol Cancer; 2015 May; 25(4):629-36. PubMed ID: 25633654
[TBL] [Abstract][Full Text] [Related]
7. Is the sarcomatous component (homologous vs heterologous) the prognostic "driving force" in early-stage uterine carcinosarcomas? A retrospective multicenter study.
Rosati A; Vargiu V; Certelli C; Arcieri M; Vizza E; Legge F; Cosentino F; Ferrandina G; Fanfani F; Scambia G; Corrado G
J Cancer Res Clin Oncol; 2023 Aug; 149(9):6479-6488. PubMed ID: 36773091
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 Expression in Carcinosarcomas of the Gynecologic Tract: A Potentially Actionable Biomarker.
Pinto A; Mackrides N; Nadji M
Appl Immunohistochem Mol Morphol; 2018 Jul; 26(6):393-397. PubMed ID: 27801734
[TBL] [Abstract][Full Text] [Related]
9. Differential expression of matrix metalloprotease-7 in each component of uterine carcinosarcoma.
Tanimoto H; Shigemasa K; Sasaki M; Katayama H; Kusumi I; Parmley TH; O'Brien TJ; Ohama K
Oncol Rep; 2000; 7(6):1209-12. PubMed ID: 11032915
[TBL] [Abstract][Full Text] [Related]
10. SATB2 Expression Is Sensitive but Not Specific for Osteosarcomatous Components of Gynecologic Tract Carcinosarcomas: A Clinicopathologic Study of 60 Cases.
Sangoi AR; Kshirsagar M; Horvai AE; Roma AA
Int J Gynecol Pathol; 2017 Mar; 36(2):140-145. PubMed ID: 27294605
[TBL] [Abstract][Full Text] [Related]
11. Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer.
Amant F; Cadron I; Fuso L; Berteloot P; de Jonge E; Jacomen G; Van Robaeys J; Neven P; Moerman P; Vergote I
Gynecol Oncol; 2005 Aug; 98(2):274-80. PubMed ID: 15972232
[TBL] [Abstract][Full Text] [Related]
12. High glucocorticoid receptor expression in the sarcomatous versus carcinomatous elements of Mullerian carcinosarcomas.
Kurnit KC; Steiner M; Lastra RR; Weroha SJ; Cursio J; Lengyel E; Fleming GF; Conzen SD
Gynecol Oncol Rep; 2022 Jun; 41():100987. PubMed ID: 35519002
[TBL] [Abstract][Full Text] [Related]
13. Molecular markers and clinical behavior of uterine carcinosarcomas: focus on the epithelial tumor component.
de Jong RA; Nijman HW; Wijbrandi TF; Reyners AK; Boezen HM; Hollema H
Mod Pathol; 2011 Oct; 24(10):1368-79. PubMed ID: 21572397
[TBL] [Abstract][Full Text] [Related]
14. Carcinosarcomas of the uterus and ovary: a clinicopathologic and immunohistochemical study of 11 cases.
Kondi-Pafiti A; Grapsa D; Hasiakos D; Gennatas K; Fotiou S
Eur J Gynaecol Oncol; 2009; 30(1):93-7. PubMed ID: 19317268
[TBL] [Abstract][Full Text] [Related]
15. Predictive Histologic Factors in Carcinosarcomas of the Uterus: A Multi-institutional Study.
Abdulfatah E; Lordello L; Khurram M; Van de Vijver K; Alosh B; Bandyopadhyay S; Oliva E; Ali-Fehmi R
Int J Gynecol Pathol; 2019 May; 38(3):205-215. PubMed ID: 30958427
[TBL] [Abstract][Full Text] [Related]
16. EGFR expression and HER2/neu overexpression/amplification in endometrial carcinosarcoma.
Livasy CA; Reading FC; Moore DT; Boggess JF; Lininger RA
Gynecol Oncol; 2006 Jan; 100(1):101-6. PubMed ID: 16157366
[TBL] [Abstract][Full Text] [Related]
17. Role of epithelial-mesenchymal transition factors in the histogenesis of uterine carcinomas.
Franceschi T; Durieux E; Morel AP; de Saint Hilaire P; Ray-Coquard I; Puisieux A; Devouassoux-Shisheboran M
Virchows Arch; 2019 Jul; 475(1):85-94. PubMed ID: 30739164
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological analysis of c-kit expression in carcinosarcomas and leiomyosarcomas of the uterine corpus.
Winter WE; Seidman JD; Krivak TC; Chauhan S; Carlson JW; Rose GS; Birrer MJ
Gynecol Oncol; 2003 Oct; 91(1):3-8. PubMed ID: 14529656
[TBL] [Abstract][Full Text] [Related]
19. Carcinosarcomas of the female genital tract. A pathologic study of 29 metastatic tumors: further evidence for the dominant role of the epithelial component and the conversion theory of histogenesis.
Sreenan JJ; Hart WR
Am J Surg Pathol; 1995 Jun; 19(6):666-74. PubMed ID: 7755153
[TBL] [Abstract][Full Text] [Related]
20. An immunohistochemical analysis of CD3, PD-L1, and CTLA-4 expression in carcinosarcomas of the gynecological tract and their metastases.
Karpathiou G; Chauleur C; Dal Col P; Dridi M; Hathroubi S; Mobarki M; Peoc'h M
Pathol Res Pract; 2020 Aug; 216(8):153028. PubMed ID: 32703493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
